New Collaborations and Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma to Establish US Operations
Santaris PharmaAppoints Art Levin Ph.D. as President of US Operations and Chief Development Officer
To spearhead the US expansion, Santaris Pharma A/S has appointed Arthur A. Levin, PhD, as President of its US operations. In addition, Dr. Levin will hold global responsibility as Vice President and Chief Development Officer of Santaris Pharma A/S.
Dr. Levin has 15 years of experience in RNA-based research and more than 25 years of experience in the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Dr. Levin was Senior Vice President of Drug Development at Isis Pharmaceuticals where he was instrumental in advancing more than a dozen RNA-based antisense drugs from basic research to clinical development.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.